First line for content
second line for content
First line for content
second line for content
First line for content
second line for content
First line for content
second line for content
Dr. John B. Marshall founded Aingeal in 2017 – a drug discovery company, which aims to develop drugs that enhance the activity of endogenous neurotrophic factors to improve brain health. The current focus of his research is on neurological disorders that affect synaptic plasticity and cognition. These include disorders on the autism spectrum, psychiatric and traumatic brain injuries.
His current invention is a novel series of cyclic peptidomimetic compounds which act on NMDA receptors and potentiate BDNF action to produce rapid antidepressant effects.
Dr. Marshall is currently a professor and faculty member at Brown University. His academic background includes a PhD from Cambridge University, U.K., Post-doctoral Fellow and Assistant Professor of Pharmacology at Yale University.
Dr. Assad J. Kazeminy is the Founder and the former CEO of Irvine Pharmaceutical Services Inc. (CRO) and Avrio Biopharmaceutical LLC (CMO) which he founded in 1988 and 2008 and in 2016, sold them to one of the largest Japanese firms Nitto Denko Avecia.
Dr. Kazeminy also serves part-time on a number of Executive Boards and Councils; Thera Vida Inc, Physical Science Dean’s Leadership Council at University of California Irvine, External Advisor to the Department of Chemistry, UCI Applied Innovation, Chapman University School of Pharmacy, and many more.
Dr. Kazeminy received his doctorate degree in Pharmaceutical Sciences from Isfahan University in Isfahan, Iran, and a post-doctorate at the University of Southern California (USC) Medical School, Department of Pharmacology.
Ms. Illuri is a career management consultant to the Life Sciences and Healthcare industries. For over 20+ years, she has delivered enterprise-wide, global, business transformation programs within Pharma R&D for Fortune 100 companies. She also has advised healthcare start-ups in the clinical trials space on product design and market entry strategies.
Her past employers and clients include Big 4 consulting and Big Pharma (Ernst & Young, Deloitte, Roche, Novartis, Genentech, Abbott Labs).
Ms. Illuri's academic background includes an M.S. in Electrical Engineering & Computer Science, from University of Illinois; Executive education in Corporate Finance, from London Business School, and Health Policy/Economics from Harvard University, respectively.
She is trilingual and holds American, British, and Indian citizenships.
Ayumi became involved with drug development working with the Strategic Project Development team at the Harrington Discovery Institute (HDI) with expertise in chemistry, ADME, DMPK, pharmacology, and translational research guiding the Angelman Syndrome Project.
She co-wrote the STTR grant with Prof. John Marshall which was awarded by the National Institute of Mental Health (NIMH) in September of 2019.
Prior to her work in drug development, Ayumi investigated neuronal circuits underlying addiction and pain at Brown University with Dr. Julie Kauer in the Department of Molecular Pharmacology, Physiology, and Biotechnology during her undergraduate and post-graduate years. There, she co-authored multiple publications elucidating the pathways that govern reward, addiction, and pain.
Dr. Edith Mathiowitz is a full-time Professor of Medical Science and Engineering at Brown University in the Department of Molecular Pharmacology, Physiology & Biotechnology. She is also the Director of the Biotechnology Graduate Program.
Her extensive experience includes development of polymers that are used in drug and gene delivery systems and tissue engineering applications, including stem cell recruitment.
Following her undergraduate degree in physical chemistry and graduate school at the Weizmann institute of science, Dr. Mathiowitz trained as a post-doctoral associate with Professor Robert Langer.
